Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:27 2025-06-20 am EDT			5-day change	1st Jan Change
94.89 ^CHF	-0.34%		-2.34%	+6.98%

Jun. 19	NOVARTIS AG : Deutsche Bank maintains a Buy rating	ZD
Jun. 19	Swiss trade surplus at CHF 3.831 bln in May	RE

Swiss Market Index Closes in the Green on Healthcare Stocks Boost

Published on 02/19/2024 at 11:53, updated on 02/19/2024 at 11:54

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

NOVARTIS AG : Deutsche Bank maintains a Buy rating	Jun. 19	ZD
Swiss trade surplus at CHF 3.831 bln in May	Jun. 19	RE
Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown, Bloomberg reports	Jun. 17	MT
NOVARTIS AG : UBS sticks Neutral	Jun. 16	ZD
Swiss Market Index Close Little Changed; Novartis Shares Rise	Jun. 12	MT
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH	Jun. 12	MT
Novartis: Fabhalta approved for a new population	Jun. 12	CF
NOVARTIS AG : Berenberg reiterates its Neutral rating	Jun. 12	ZD
Novartis' Fabhalta Shows Reduced Hemoglobin Levels in Late-stage Trial	Jun. 12	MT
Novartis Says Fabhalta® Shows Statistically Significant And Clinically Meaningful Improvements In Hemoglobin In New Population Of Patients With Pnh	Jun. 12	RE
Novartis Fabhalta(R) shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH	Jun. 12	DJ
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	Jun. 11	DJ
New purchases in the European Investor portfolio	Jun. 10
NOVARTIS AG : Deutsche Bank gives a Buy rating	Jun. 09	ZD
Otsuka's kidney disease therapy trial results heat up battle with rival Vera	Jun. 06	RE
Further market approval for Formycon's Lucentis biosimilar - share price rises	Jun. 05	DP
Formycon receives market approval in Brazil for Lucentis biosimilar	Jun. 05	DP
Health insurers in favor of cost containment for drug spending	Jun. 03	DP
Swiss Shares in Red as Trade Worries Overtake Q1 GDP Growth Beat	Jun. 02	MT
Novartis Reports New Data From Phase 2 Trial of Kisqali in Breast Cancer	Jun. 02	MT
Novartis Says Pluvicto Shows Benefit in Early Prostate Cancer Study	Jun. 02	MT
Novartis Announces Topline Results from Pre-Specified Interim Analysis of the Phase III PSMAddition Trial	Jun. 02	CI
European Midday Briefing : Stocks Mostly Drop as Trade Tensions Flare	Jun. 02	DJ

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company